- Home
- NEGG vs IKNA Comparison
NEGG vs IKNA Comparison
Compare NEGG & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- IKNA
- Stock Information
- Founded
- NEGG 2001
- IKNA 2016
- Country
- NEGG United States
- IKNA United States
- Employees
- NEGG N/A
- IKNA N/A
- Industry
- NEGG Other Specialty Stores
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- IKNA Health Care
- Exchange
- NEGG Nasdaq
- IKNA Nasdaq
- Market Cap
- NEGG 75.6M
- IKNA 61.8M
- IPO Year
- NEGG 2010
- IKNA 2021
- Fundamental
- Price
- NEGG $3.98
- IKNA $1.11
- Analyst Decision
- NEGG
- IKNA Buy
- Analyst Count
- NEGG 0
- IKNA 2
- Target Price
- NEGG N/A
- IKNA $3.00
- AVG Volume (30 Days)
- NEGG 43.9K
- IKNA 84.2K
- Earning Date
- NEGG 04-28-2025
- IKNA 05-12-2025
- Dividend Yield
- NEGG N/A
- IKNA N/A
- EPS Growth
- NEGG N/A
- IKNA N/A
- EPS
- NEGG N/A
- IKNA N/A
- Revenue
- NEGG $1,391,833,000.00
- IKNA N/A
- Revenue This Year
- NEGG $6.01
- IKNA N/A
- Revenue Next Year
- NEGG N/A
- IKNA N/A
- P/E Ratio
- NEGG N/A
- IKNA N/A
- Revenue Growth
- NEGG N/A
- IKNA N/A
- 52 Week Low
- NEGG $3.52
- IKNA $0.97
- 52 Week High
- NEGG $26.40
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- NEGG 34.67
- IKNA 38.47
- Support Level
- NEGG $3.72
- IKNA $1.06
- Resistance Level
- NEGG $4.22
- IKNA $1.25
- Average True Range (ATR)
- NEGG 0.56
- IKNA 0.10
- MACD
- NEGG 0.02
- IKNA 0.00
- Stochastic Oscillator
- NEGG 22.12
- IKNA 39.83
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.